Tigecycline, marketed under the brand name Tygacil, is an antibiotic used to treat various infections. It belongs to a class of antibiotics called glycylcyclines. Compared to other antibiotics, tigecycline has shown effectiveness against a broad spectrum of bacteria, including some that are resistant to other antibiotics. However, a study published on the National Center for Biotechnology Information (NCBI) website highlighted concerns about an increased risk of death associated with tigecycline compared to other antibiotics [3]. The FDA has also issued a drug safety communication regarding this increased risk of death when using tigecycline compared to other antibiotics [2]. This information underscores the importance of considering the risks and benefits of tigecycline in comparison to other available antibiotic medications when making treatment decisions.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE
[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1426172/